Abstract

Adult T-cell leukemia/lymphoma (ATL) is caused by human T-cell leukemia virus type 1 (HTLV-1). In addition to HTLV-1 bZIP factor (HBZ), a leukemogenic antisense transcript of HTLV-1, abnormalities of genes involved in TCR-NF-κB signaling, such as CARD11, are detected in about 90% of patients. Utilizing mice expressing CD4+ T cell-specific CARD11(E626K) and/or CD4+ T cell-specific HBZ, namely CARD11(E626K)CD4-Cre mice, HBZ transgenic (Tg) mice, and CARD11(E626K)CD4-Cre;HBZ Tg double transgenic mice, we clarify these genes’ pathogenetic effects. CARD11(E626K)CD4-Cre and HBZ Tg mice exhibit lymphocytic invasion to many organs, including the lungs, and double transgenic mice develop lymphoproliferative disease and increase CD4+ T cells in vivo. CARD11(E626K) and HBZ cooperatively activate the non-canonical NF-κB pathway, IRF4 targets, BATF3/IRF4/HBZ transcriptional network, MYC targets, and E2F targets. Most KEGG and HALLMARK gene sets enriched in acute-type ATL are also enriched in double transgenic mice, indicating that these genes cooperatively contribute to ATL development.

The oncogenic ability of mutant CARD11 (E626K), one of most frequently mutated genes in adult T-cell leukemia and its cooperative effect with HBZ expression, using the CD4 promoter-driven HBZ transgenic mouse model, is investigated.

Details

Title
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma
Author
Kameda, Takuro 1   VIAFID ORCID Logo  ; Shide, Kotaro 1 ; Kamiunten, Ayako 1 ; Kogure, Yasunori 2   VIAFID ORCID Logo  ; Morishita, Daisuke 3 ; Koya, Junji 2 ; Tahira, Yuki 1 ; Akizuki, Keiichi 1 ; Yokomizo-Nakano, Takako 4 ; Kubota, Sho 4 ; Marutsuka, Kosuke 5 ; Sekine, Masaaki 1 ; Hidaka, Tomonori 1 ; Kubuki, Yoko 1 ; Kitai, Yuichi 6 ; Matsuda, Tadashi 6 ; Yoda, Akinori 7 ; Ohshima, Takayuki 8   VIAFID ORCID Logo  ; Sugiyama, Midori 9 ; Sashida, Goro 4   VIAFID ORCID Logo  ; Kataoka, Keisuke 10 ; Ogawa, Seishi 7   VIAFID ORCID Logo  ; Shimoda, Kazuya 1   VIAFID ORCID Logo 

 University of Miyazaki, Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, Miyazaki, Japan (GRID:grid.410849.0) (ISNI:0000 0001 0657 3887) 
 National Cancer Center Research Institute, Division of Molecular Oncology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385) 
 Chordia Therapeutics, Fujisawa, Japan (GRID:grid.272242.3) 
 Kumamoto University, Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto, Japan (GRID:grid.274841.c) (ISNI:0000 0001 0660 6749) 
 Miyazaki Prefectural Miyazaki Hospital, Department of Anatomic Pathology, Miyazaki, Japan (GRID:grid.274841.c) 
 Hokkaido University, Department of Immunology, Graduate School of Pharmaceutical Sciences, Sapporo, Japan (GRID:grid.39158.36) (ISNI:0000 0001 2173 7691) 
 Kyoto University, Department of Pathology and Tumor Biology, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
 Tokushima Bunri University, Faculty of Pharmaceutical Sciences at Kagawa Campus, Kagawa, Japan (GRID:grid.412769.f) (ISNI:0000 0001 0672 0015) 
 Chordia Therapeutics, Fujisawa, Japan (GRID:grid.412769.f) 
10  National Cancer Center Research Institute, Division of Molecular Oncology, Tokyo, Japan (GRID:grid.272242.3) (ISNI:0000 0001 2168 5385); Keio University School of Medicine, Division of Hematology, Department of Medicine, Tokyo, Japan (GRID:grid.26091.3c) (ISNI:0000 0004 1936 9959) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
23993642
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2741155328
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.